DIQTA 1.0: Drug-Induced QT Prolongation Atlas

PIMOZIDE

DIR Classification Postmarketing Surveillance Drug Property Information Reference

DIR Classification

Classification:Most-DIQT concern

Severity Score:4.0

Description in Drug Labeling: View Full Labeling: SPL in DailyMed | PDF

WARNINGS
Other
Sudden, unexpected deaths have occurred in experimental studies of conditions other than Tourette's Disorder. These deaths occurred while patients were receiving dosages in the range of 1 mg per kg. One possible mechanism for such deaths is prolongation of the QT interval predisposing patients to ventricular arrhythmia. An electrocardiogram should be performed before pimozide treatment is initiated and periodically thereafter, especially during the period of dose adjustment.
PRECAUTIONS
LABORATORY TESTS
An ECG should be done at baseline and periodically thereafter throughout the period of dose adjustment. Any indication of prolongation of QTc interval beyond an absolute limit of 0.47 seconds (children) or 0.52 seconds (adults), or more than 25% above the patient’s original baseline should be considered a basis for stopping further dose increase (see CONTRAINDICATIONS) and considering a lower dose.
[DRUG INTERACTIONS]
Because pimozide prolongs the QT interval of the electrocardiogram, an additive effect on QT interval would be anticipated if administered with other drugs, such as phenothiazines, tricyclic antidepressants or antiarrhythmic agents, which prolong the QT interval. Accordingly, pimozide should not be given with dofetilide, sotalol, quinidine, other Class Ia and III anti-arrhythmics, mesoridazine, thioridazine, chlorpromazine, droperidol, sparfloxacin, gatifloxacin, moxifloxacin, halofantrine, mefloquine, pentamidine, arsenic trioxide, levomethadyl acetate, dolasetron mesylate, probucol, tacrolimus, ziprasidone, or other drugs that have demonstrated QT prolongation as one of their pharmacodynamic effects. Also, the use of macrolide antibiotics in patients with prolonged QT intervals has been rarely associated with ventricular arrhythmias. Such concomitant administration should not be undertaken (see CONTRAINDICATIONS).
Pimozide and Celexa: In a controlled study, a single dose of pimozide 2 mg coadministered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of Pimozide and Celexa or Lexapro is contraindicated (See CONTRAINDICATIONS).
CONTRAINDICATIONS
Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - Drug Interactions).
Ventricular arrhythmias have been rarely associated with the use of macrolide antibiotics in patients with prolonged QT intervals, as might be produced by pimozide. Specifically, two sudden deaths have been reported when clarithromycin was added to ongoing pimozide therapy.Furthermore, some evidence suggests that pimozide is metabolized partly by the enzyme system cytochrome P450 3A4 (CYP 3A4). Macrolide antibiotics are inhibitors of CYP 3A4, and thus could potentially impede pimozide metabolism. For these reasons, pimozide is contraindicated in patients receiving the macrolide antibiotics clarithromycin, erythromycin, azithromycin,dirithromycin, and troleandomycin.
ADVERSE REACTIONS
Electrocardiographic Changes: Electrocardiographic changes have been observed in clinical trials of pimozide in Tourette’s Disorder and schizophrenia. These have included prolongation of the QT interval, flattening, notching and inversion of the T wave and the appearance of U waves. Sudden, unexpected deaths and grand mal seizure have occurred at doses above 20 mg/day.

Postmarketing Surveillance

Contingency Table:

Current Drug

Other Drugs

QT Prolongation

24080

Other ADRs

2789

38378798

Odds Ratio = 6.858

Drug Property Information

ATC Code(s):

N05AG02 - pimozide

N05AG - Diphenylbutylpiperidine derivatives
N05A - ANTIPSYCHOTICS
N05 - PSYCHOLEPTICS
N - NERVOUS SYSTEM

Active Ingredient:PIMOZIDE

Active Ingredient UNII:1HIZ4DL86F

Drugbank ID:DB01100

PubChem Compound:16362

CTD ID:D010868

PharmGKB:PA450965

CAS Number:2062-78-4

Dosage Form(s):tablet

Route(s) Of Administrator:oral

Daily Dose:

4.0 mg/day N05AG02

Chemical Structure:

SMILE Code:
FC1=CC=C(C=C1)C(CCCN1CCC(CC1)N1C(=O)NC2=CC=CC=C12)C1=CC=C(F)C=C1

Reference

1: Gastrointestinal absorption of pimozide is enhanced by inhibition of P-glycoprotein.

[Morishita Hiroki,Okawa Kozue,Ishii Misaki,Mizoi Kenta,Ito Masa-Aki,Arakawa Hiroshi,Yano Kentaro,Ogihara Takuo]
PLoS One,2020 Oct 29;15(10):e0232438. PMID: 33119612

2: Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis.

[Huhn Maximilian,Nikolakopoulou Adriani,Schneider-Thoma Johannes,Krause Marc,Samara Myrto,Peter Natalie,Arndt Thomas,Bäckers Lio,Rothe Philipp,Cipriani Andrea,Davis John,Salanti Georgia,Leucht Stefan]
Lancet,2019 Sep 14;394(10202):939-951. PMID: 31303314

3: Coprescription of QT interval-prolonging antipsychotics with potentially interacting medications in Thailand.

[Waleekhachonloet Onanong,Limwattananon Chulaporn,Rattanachotphanit Thananan]
Ther Adv Drug Saf,2019 Jun 13;10:2042098619854886. PMID: 31223470

4: CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.

[Kitaguchi Takashi,Moriyama Yuta,Taniguchi Tomohiko,Maeda Sanae,Ando Hiroyuki,Uda Takaaki,Otabe Koji,Oguchi Masao,Shimizu Shigekazu,Saito Hiroyuki,Toratani Atsushi,Asayama Mahoko,Yamamoto Wataru,Matsumoto Emi,Saji Daisuke,Ohnaka Hiroki,Miyamoto Norimasa]
J Pharmacol Toxicol Methods,May-Jun 2017;85:73-81. PMID: 28163191

5: Specific prediction of clinical QT prolongation by kinetic image cytometry in human stem cell derived cardiomyocytes.

[Pfeiffer Emily R,Vega Raquel,McDonough Patrick M,Price Jeffrey H,Whittaker Ross]
J Pharmacol Toxicol Methods,Sep-Oct 2016;81:263-73. PMID: 27095424

6: Antipsychotic Polypharmacy and Corrected QT Interval: A Systematic Review.

[Takeuchi Hiroyoshi,Suzuki Takefumi,Remington Gary,Uchida Hiroyuki]
Can J Psychiatry,2015 May;60(5):215-22. PMID: 26174525

7: Corrected QT changes during antipsychotic treatment of children and adolescents: a systematic review and meta-analysis of clinical trials.

[Jensen Karsten Gjessing,Juul Klaus,Fink-Jensen Anders,Correll Christoph U,Pagsberg Anne Katrine]
J Am Acad Child Adolesc Psychiatry,2015 Jan;54(1):25-36. PMID: 25524787

8: QTc prolongation: is clozapine safe? Study of 82 cases before and after clozapine treatment.

[Grande Iria,Pons Alexandre,Baeza Immaculada,Torras Ángela,Bernardo Miguel]
Hum Psychopharmacol,2011 Aug;26(6):397-403. PMID: 21826738

9: Cardiovascular safety of aripiprazole and pimozide in young patients with Tourette syndrome.

[Gulisano Mariangela,Calì Paola V,Cavanna Andrea E,Eddy Clare,Rickards Hugh,Rizzo Renata]
Neurol Sci,2011 Dec;32(6):1213-7. PMID: 21732066

10: Values of using QTc and N-terminal fragment of B-type natriuretic peptide as markers for early detection of acute antipsychotic drugs-induced cardiotoxicity.

[Khalaf Mohamed A M,Abdelrahman Tarek M,Abbas Mohamed F]
Cardiovasc Toxicol,2011 Mar;11(1):10-7. PMID: 21234705

11: Aripiprazole as a viable alternative for treating delusions of parasitosis.

[Ladizinski Barry,Busse Kristine L,Bhutani Tina,Koo John Y M]
J Drugs Dermatol,2010 Dec;9(12):1531-2. PMID: 21120263

12: Iatrogenic QT Abnormalities and Fatal Arrhythmias: Mechanisms and Clinical Significance.

[Cubeddu Luigi X]
Curr Cardiol Rev,2009 Aug;5(3):166-76. PMID: 20676275

13: QT alterations in psychopharmacology: proven candidates and suspects.

[Alvarez Paulino Antonio,Pahissa Jaime]
Curr Drug Saf,2010 Jan;5(1):97-104. PMID: 20210726

14: [Potentially lethal cardiac side effects caused by psychiatric drugs].

[Sawicke Luciana,Sturla Soledad]
Vertex,Nov-Dec 2008;19(82):387-93. PMID: 19424522

15: Cardiac side effects of psychiatric drugs.

[Mackin Paul]
Hum Psychopharmacol,2008 Jan;23 Suppl 1:3-14. PMID: 18098218

16: Evaluation of the guinea pig monophasic action potential (MAP) assay in predicting drug-induced delay of ventricular repolarisation using 12 clinically documented drugs.

[Kågström Jens,Sjögren Eva-Lena,Ericson Ann-Christin]
J Pharmacol Toxicol Methods,Sep-Oct 2007;56(2):186-93. PMID: 17582787

17: QT PRODACT: in vivo QT assay in the conscious dog for assessing the potential for QT interval prolongation by human pharmaceuticals.

[Toyoshima Shigeki,Kanno Akihiro,Kitayama Tetsuya,Sekiya Koji,Nakai Keiko,Haruna Masao,Mino Terumasa,Miyazaki Hiroyasu,Yano Koji,Yamamoto Keiji]
J Pharmacol Sci,2005;99(5):459-71. PMID: 16493187

18: In vivo recording of adult zebrafish electrocardiogram and assessment of drug-induced QT prolongation.

[Milan David J,Jones Ian L,Ellinor Patrick T,MacRae Calum A]
Am J Physiol Heart Circ Physiol,2006 Jul;291(1):H269-73. PMID: 16489111

19: Antipsychotic drugs and QT prolongation.

[Stöllberger Claudia,Huber Johannes O,Finsterer Josef]
Int Clin Psychopharmacol,2005 Sep;20(5):243-51. PMID: 16096514

20: Delayed dystonia following pimozide overdose in a child.

[Gair Robert D,Friesen Marjorie S,Kent Debra A]
J Toxicol Clin Toxicol,2004;42(7):977-81. PMID: 15641643

21: QTc prolongation due to propranolol overdose.

[Farhangi Vida,Sansone Randy A]
Int J Psychiatry Med,2003;33(2):201-2. PMID: 12968835

22: A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.

[Kongsamut Sathapana,Kang Jiesheng,Chen Xiao-Liang,Roehr Joachim,Rampe David]
Eur J Pharmacol,2002 Aug 16;450(1):37-41. PMID: 12176106

23: Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

[Haddad Peter M,Anderson Ian M]
Drugs,2002;62(11):1649-71. PMID: 12109926

24: Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death.

[Glassman A H,Bigger J T]
Am J Psychiatry,2001 Nov;158(11):1774-82. PMID: 11691681

25: Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes.

[Drolet B,Rousseau G,Daleau P,Cardinal R,Simard C,Turgeon J]
J Cardiovasc Pharmacol Ther,2001 Jul;6(3):255-60. PMID: 11584332

26: Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition.

[Dresser G K,Spence J D,Bailey D G]
Clin Pharmacokinet,2000 Jan;38(1):41-57. PMID: 10668858

27: Case report: reversible QT prolongation with torsades de pointes in a patient with pimozide intoxication.

[Krähenbühl S,Sauter B,Kupferschmidt H,Krause M,Wyss P A,Meier P J]
Am J Med Sci,1995 Jun;309(6):315-6. PMID: 7771501

Search for drugs: